論文 - 詳細
| RRC ID | 5725 |
|---|---|
| 著者 | Mitsuyama J, Nomura N, Hashimoto K, Yamada E, Nishikawa H, Kaeriyama M, Kimura A, Todo Y, Narita H. |
| タイトル | In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. |
| ジャーナル | Antimicrob Agents Chemother |
| Abstract |
The in vitro and in vivo antifungal activities of T-2307, a novel arylamidine, were evaluated and compared with those of fluconazole, voriconazole, micafungin, and amphotericin B. T-2307 exhibited broad-spectrum activity against clinically significant pathogens, including Candida species (MIC range, 0.00025 to 0.0078 microg/ml), Cryptococcus neoformans (MIC range, 0.0039 to 0.0625 microg/ml), and Aspergillus species (MIC range, 0.0156 to 4 microg/ml). Furthermore, T-2307 exhibited potent activity against fluconazole-resistant and fluconazole-susceptible-dose-dependent Candida albicans strains as well as against azole-susceptible strains. T-2307 exhibited fungicidal activity against some Candida and Aspergillus species and against Cryptococcus neoformans. In mouse models of disseminated candidiasis, cryptococcosis, and aspergillosis, the 50% effective doses of T-2307 were 0.00755, 0.117, and 0.391 mg.kg(-1).dose(-1), respectively. This agent was considerably more active than micafungin and amphotericin B against candidiasis and than amphotericin B against cryptococcosis, and its activity was comparable to the activities of micafungin and amphotericin B against aspergillosis. The results of preclinical in vitro and in vivo evaluations performed thus far indicate that T-2307 could represent a potent injectable agent for the treatment of candidiasis, cryptococcosis, and aspergillosis. |
| 巻・号 | 52(4) |
| ページ | 1318-24 |
| 公開日 | 2008-4-1 |
| DOI | 10.1128/AAC.01159-07 |
| PII | AAC.01159-07 |
| PMID | 18227186 |
| PMC | PMC2292552 |
| MeSH | Animals Antifungal Agents / chemistry Antifungal Agents / pharmacology* Antifungal Agents / therapeutic use Aspergillosis / drug therapy Aspergillosis / microbiology Aspergillus fumigatus / drug effects* Benzamidines / chemistry Benzamidines / pharmacology* Benzamidines / therapeutic use Candida albicans / drug effects* Candidiasis / drug therapy Candidiasis / microbiology Cryptococcosis / drug therapy Cryptococcosis / microbiology Cryptococcus neoformans / drug effects* Male Mice Mice, Inbred ICR Microbial Sensitivity Tests Mycoses / drug therapy* Mycoses / microbiology Specific Pathogen-Free Organisms Treatment Outcome |
| IF | 4.904 |
| WOS 分野 | PHARMACOLOGY & PHARMACY MICROBIOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 18 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| 一般微生物 | JCM2466 |